Human Genome keeps buy from Merrill

Merrill Lynch analyst Hari Sambasivam kept Human Genome Sciences, Inc. at buy, updating its model to include the partnerships with Novartis for Albuferon and GlaxoSmithKline for LymphoStat-B. Merrill now includes $371.5 million in milestone payments amortized over a four year period in its model. Shares of the Rockville, Md.-based biopharmaceutical company were up 7 cents, or 0.62%, at $11.45. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.